Customs Changes Expected to Halt Most Mailed Prescription Imports

Americans who receive prescription medicines by mail from Canadian and other international pharmacies face a major interruption to that access beginning October 22, 2026.

The Canadian International Pharmacy Association (CIPA) has assessed the forthcoming U.S. customs requirements and obtained information about how they will be applied. Its conclusion is that, without a change in policy or implementation, the arrangements used to deliver most personal prescription orders to U.S. patients will no longer be workable.

CIPA is sharing this warning so patients can understand the implications and have time to prepare.

How the customs changes affect prescription deliveries

October 22 is the compliance date specified for relevant provisions of the CBP rule published on June 24, 2026. The provisions change the entry procedures applicable to international mail, including shipments requiring additional information for government agencies.

Understanding the consequences for prescription medicines requires looking beyond the filing procedure. A parcel must also meet the conditions applied to the medication itself, and someone eligible must accept responsibility for its customs entry.

CIPA's concern arises from how those requirements will operate together.

The obstacle facing international postal services

A company named Zonos serves as customs broker of record for nearly all major international postal systems. Most of those systems currently have no other broker performing that function.

That makes Zonos's ability to handle pharmaceutical entries central to the continued delivery of mailed prescriptions.

CBP's new rule coupled with the FDA's policy toward imported medications under the new procedures means that Zonos will be prevented from serving as importer of record for shipments containing a pharmaceutical product that is commercially available in the United States.

These restrictions originate with CBP and FDA. They do not reflect a voluntary change in Zonos's business preferences.

The effect of this the problem: CIPA's assessment is that it captures virtually the whole ordinary market for personal prescription orders supplied to Americans by licensed Canadian and international pharmacies.

Why patient documents and electronic filings do not resolve the problem

The limitations described by CIPA are reflected in Zonos's public guidance on prescription medicines. Its explanation of personal importation excludes circumstances where effective treatment is available in the United States. It also makes clear that documents supplied by the patient cannot remedy a seller's promotion of medicines to U.S. residents.

The availability of another customs procedure, known as Entry Type 13, therefore does not establish that these prescriptions can continue to be delivered.

Under CBP's Entry Type 13 notice, the process involves an eligible importer of record, a bond, electronic submission of the entry, and any required agency data. Completing those steps does not remove the conditions governing admission of the medication.

Likewise, the existence of a policy allowing FDA discretion in certain personal-importation cases provides no assurance that a typical order from an overseas pharmacy for personal use in a quantity not exceeding 90 days will qualify. We have no reason to believe that the FDA intends to exercise that discretion in favor of consumers like they did before these new rule is implemented.

Why patients need advance warning

Some readers may expect to find a government announcement explicitly declaring an end to personal prescription imports. The published measure instead addresses customs procedures. Its consequences for patients depend on the requirements applied when their parcels reach the border.

A delivery route can become unusable through the combined effect of those requirements even without a rule expressly announcing a universal ban.

For this reason, CIPA's assessment draws on both the public documents and the implementation information it has received. Its warning concerns the expected interruption of medication deliveries under the arrangements scheduled to apply from October 22.

Unless those arrangements change, Americans should expect that virtually all routine personal prescription orders mailed from licensed Canadian and international pharmacies will be unable to reach them.

Patients deserve this information before their access is interrupted. CIPA and its members have a responsibility to give them that opportunity; waiting for parcels to be stopped would leave people with less time to make alternative arrangements.

Help stop this change before October 22

Please turn this warning into action. Join the Campaign for Personal Prescription Importation (CPPI), send its letter to your U.S. senators and representative, and explain why continued access to affordable medication matters to you. Whether you rely on these services yourself or are speaking up for someone who does, add your voice today. Please act now and ask friends and family to participate too.

Join CPPI | Send your letter now